A Randomized Clinical Trial to Evaluate the Efficacy and Safety of α-Keto Amino Acids Supplementation in stage 3 and 4 patients of Chronic Kidney Disease.
Abstract
ABSTRACT
Objective: To evaluate efficacy and safety of α- Keto Amino Acids (KAA) supplementation in stage 3 and 4 patients of Chronic Kidney Disease.
Material and Methods: The study was conducted in stage 3 and 4 patients of Chronic Kidney Disease of a tertiary care centre of north India. Patients were randomly divided into two interventional groups. Group I (Control) was given conservative management and placebo while Group II (KAA) given conservative management along with KAA (600 mg, thrice daily) for 12 weeks. Haemogram and renal function tests were done and adverse effects were recorded at 0, 4, 8 and 12 weeks of treatment.
Â
Results:Â Both groups showed gradual improvement in the biochemical parameters as compared to their pre-treated values which was more marked in KAA supplemented group. There was reduction in blood glucose, blood urea, serum creatinine and 24 hour total urine protein (TUP). There was increase in haemoglobin, 24 hour total urine volume (TUV) and glomerular filtration rate (GFR). There was no statistical difference in two groups with respect to side effects (p>0.05).
Conclusion: α-Keto amino acids (KAA) supplementation along with conservative management is efficacious and safe in preventing the progression of disease in stage 3 and 4 patients of Chronic Kidney Disease.
KEY WORDS: Keto amino acids, Glomerular filtration rate, End stage renal disease.
Downloads
References
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb; 39 (2 Suppl 1):S1-266.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt K-U, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney International 2007 June; 72 : 247–259.
Singh AK, Farag YMK, Mittal BV, Subramanian KK, Reddy SRK, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and early evaluation of kidney disease) study. BMC Nephrology 2013, 14:114.
Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney International 2003 Feb; 63(Suppl 83):S115-8.
Chang JH, Dong KK, Jung TP, Kang EW, Yoo TH, Kim BS, et al. Influence of ketoanalogs supplementation on the progression in chronic kidney disease patients who had training on low-protein diet. Nephrology 2009; 14:750–757.
Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database of Systematic Reviews 2006;2.
Haque SF, Ansari AP. Keto-Analogues of Essential Amino Acids improves the clinical outcome in patients with CKD. Journal of Medical Science & Research, 2011; 2(2):64- 66.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239 245.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. American journal of hospital pharmacy 1992; 49:2229–32.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047–53.
Gupta R. Trends in hypertension epidemiology in India. Journal of Human Hypertension 2004; 18(2):73–8.
Kher V. End-stage renal disease in developing countries. Kidney Int. 2002; 62(1):350–62.
Richards P, Metcalfe-Gibson A, Ward EE, Wrong O and Houghton BJ. Utilisation of ammonia nitrogen for protein synthesis in man, and the effect of protein restriction and uraemia. Lancet, 1967;2: 845.
Teplan V. Supplements of Keto Acids in patients with chronic renal failure. Nefroloji Dergisi 2004;13(1):3-7.
Ell S, Fynn M, Richards P and Halliday D. Metabolic studies with keto acid diets. The American Journal of Clinical Nutrition, 1978; 31: 1776-1783.
Aparicio M, Gin H, Potaux L, Bouchet JL, Morel D, Aubertin J. Effect of a ketodiet on glucose tolerance and tissue insulin sensitivity. Kidney Int. 1989; Suppl 27:231-235.
Chen N, Jin Y, Ren H, Jing,Shen P, Huang X. Anti-inflammatory effects of low protein diet supplemented with keto-amino acid in the treatment of type 2 diabetic nephropathy. Kidney Research and Clinical Practice, 2012 June;31(2): A24.
Chen JB, Cheng BC, Kao TW. A comparison of progression of chronic renal failure: low dose vs standard dose ketoacids. Kidney Research and Clinical Practice, 2012 June;31(2): A24.
Walser M, Coulter W, Dighe S and Crantz FR. The effect of keto-analogues of essential amino acids in severe chronic uremia. The Journal of Clinical Investigation, 1973 March; 52:678-690.
Mitch WE, Abras E, Walser M. Long-term effects of a new ketoacid-amino acid supplement in patients with chronic renal failure. Kidney Int. 1982 Jul; 22(1):48-53.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.